Oncology Clinical Studies
Managing Efficient Oncology Clinical Trials to Drive Successful Outcomes is not just our Mission; it is our Passion.
Navitas Life Sciences stands out as a leading Oncology CRO (Clinical Research Organization) with unmatched expertise. Our unique master protocol approach ensures a seamless integration of participant recruitment, site management, data management, medical monitoring, and other critical activities. We guarantee the implementation of efficient and effective clinical trials oncology-specific designs, optimizing resource allocation and enhancing risk management, with quick identification of potential issues.
Navitas Life Sciences: Leverage our 100+ Oncology Clinical Study Expertise.
Navitas Life Sciences' commitment to innovation is evident in our extensive experience with both solid and hematological tumors, including breast, lung, gastric, HCC, prostate, multiple myeloma, AML, lymphoma, and leukemia. Powering possibilities with cutting-edge technology led oncology cro services, our expertise aligns with the latest advancements in cancer immunotherapy, driving successful outcomes.
Our Oncology CRO Solutions Include:
Protocol Amendment Management
Manage multiple protocol amendments in complex innovative designs.
Comprehensive Statistical Support
Offer sharp statistical support for CID, addressing potential biases, interim analysis, design modifications, early stopping based on futility analysis, and Bayesian statistics.
Expert Medical Support
Provide medical support with in-depth understanding of targeted therapies, precise eligibility based on biomarkers, specific genetic aberrations, radiological assessments (RECIST, irRECIST, RANO for neuro-oncology), and toxicity assessment (DLTs, MTD, CTCAE grading).
AI-Powered Analytics
Leverage artificial intelligence support through our in-house AI/ML technology platform, OneClinical Analytics.
Regulatory Excellence
Excellent compliance record with commitment to the highest regulatory standards. Flawless history with the USFDA and zero 483 observations.
Multiple Therapeutic Solutions Support
Targeted therapy, proteasome inhibitors, small molecule therapies, innate immunity enhancers, check point inhibitors, monoclonal antibodies, redirected immunity, immunomodulators, hormone therapies, cancer vaccines, and more.
Extensive Experience across Cancer Types
Stellar support for cancerous states including solid, metastatic, hematological, “in situ” carcinomas, sarcomas, undifferentiated, lymphomas, blastomas, melanomas, germ cell, carcinosarcoma, brain cancers, and other tumours.
Advanced Dose Escalation Studies
Conduct dose escalation studies using both rule-based (traditional 3+3, accelerated titration) and model-based designs (modified CRM, time-to-event CRM).
Master Protocol Implementation
Implement master protocols for umbrella, basket, and platform trials.
Tailored Trial Approaches
Tailor approaches for trials with registrational intent versus exploratory trials assessing surrogate markers.
Protocol Amendment Management
Manage multiple protocol amendments in complex innovative designs.
Comprehensive Statistical Support
Offer sharp statistical support for CID, addressing potential biases, interim analysis, design modifications, early stopping based on futility analysis, and Bayesian statistics.
Expert Medical Support
Provide medical support with in-depth understanding of targeted therapies, precise eligibility based on biomarkers, specific genetic aberrations, radiological assessments (RECIST, irRECIST, RANO for neuro-oncology), and toxicity assessment (DLTs, MTD, CTCAE grading).
AI-Powered Analytics
Leverage artificial intelligence support through our in-house AI/ML technology platform, OneClinical Analytics.
Regulatory Excellence
Excellent compliance record with commitment to the highest regulatory standards. Flawless history with the USFDA and zero 483 observations.
Multiple Therapeutic Solutions Support
Targeted therapy, proteasome inhibitors, small molecule therapies, innate immunity enhancers, check point inhibitors, monoclonal antibodies, redirected immunity, immunomodulators, hormone therapies, cancer vaccines, and more.
Extensive Experience across Cancer Types
Stellar support for cancerous states including solid, metastatic, hematological, “in situ” carcinomas, sarcomas, undifferentiated, lymphomas, blastomas, melanomas, germ cell, carcinosarcoma, brain cancers, and other tumours.
Advanced Dose Escalation Studies
Conduct dose escalation studies using both rule-based (traditional 3+3, accelerated titration) and model-based designs (modified CRM, time-to-event CRM).
Master Protocol Implementation
Implement master protocols for umbrella, basket, and platform trials.
Tailored Trial Approaches
Tailor approaches for trials with registrational intent versus exploratory trials assessing surrogate markers.
On-Demand Webinar
Innovation & Optimization in Early Phase Oncology Studies
Find out how innovative designs in early phase oncology clinical trials enhance time and cost efficiency, and optimize agent development, with expert insights on dose escalation and novel endpoints.
CASE STUDY
Successful First-In-Human Phase-I Study in Advanced Solid Malignancies
In this cancer case study, learn how we ensured 100% Successful Complex First-In-Human (FIH) Phase-I multicentre, open-label, dose-escalation study in adult patients with advanced solid malignancies.
ARTICLE
Novel approaches in early phase Oncology trials to revolutionize Cancer care
Published in: Pharma Focus Asia
Explore how the pursuit for effective treatment modalities for cancer rides on sustained efforts with catalyzed adoption of technological advancements that surpass traditional paradigms.
Explore how the pursuit for effective treatment modalities for cancer rides on sustained efforts with catalyzed adoption of technological advancements that surpass traditional paradigms.
Extensive Experience in Managing Efficient Oncology Clinical Trials
0
Professionals incl. Doctors, PhDs, Biostatisticians, Pharmacologists
0
Oncology Trials
0
Managed Sites
0
Managed Patients
Gain the Navitas Life Sciences Edge
Holistic Approach
Balancing scientific rigor with cost-effectiveness.
8 Offices World Wide
Including 4 delivery centers across the globe.
Specialized Focus
Expertise in vulnerable populations and niche areas.
Strategic Support
From TPP to regulatory compliance, we cover all bases.
Expert Team
Medical monitors with rich academic and industry experience.
BLOGS
5 Must Have Features in an Oncology CRO
Explore five essential features to look for in an Oncology Clinical Trial Contract Research Organization (CRO).
Recent Advances in Cancer Research and Treatment
Get latest trends and updates in oncology clinical trials include cancer vaccines, personalised cancer treatment and seven-minute cancer treatment injection.
Highlighting our Stellar Clinical Trial Capabilities in Thailand
Our state-of-the-art capabilities in Thailand, Malaysia and Philippines, establish us a strategic partner in the South East Asian Region, and our standing as a global CRO.